Our lead assets are being developed as treatments for Hepatitis D and Acute Respiratory Infection (ARI).
Pipeline
| Candidate | Disease | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Jitixib® (Lonafarnib) | Chronic Hepatitis D | |||
| Peginterferon lambda-1a (Lambda) | Chronic Hepatitis D* | |||
| Peginterferon lambda-1a (Lambda) | Acute Respiratory Infection (ARI) | |||
| Info | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| Candidate: Jitixib® (Lonafarnib) Disease: Chronic Hepatitis D |
|||
| Candidate: Peginterferon lambda-1a (Lambda) Disease: Chronic Hepatitis D* |
|||
| Candidate: Peginterferon lambda-1a (Lambda) Disease: Acute Respiratory Infection (ARI) |
|||
*Lambda for Chronic Hepatitis D is currently on clinical hold by FDA
**Upon FDA approval